Pfizer shares experienced a healthy 7.71% gain today as the company announced a patent victory on its biggest selling drug. This stock is technically interesting because it gapped up toward the combined resistance of the October highs and the 200 DMA. These levels have prevented the bulls from pushing the price higher on several previous occasions, and we believe that this may be the case again.



PFE_121905.jpg

Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

You May Also Like